阿哌沙班用于肥胖合并急性淋巴细胞白血病患儿血栓预防的安全性与有效性
PREVAPIX-ALL 是一项开放标签随机对照试验的事前肥胖亚组分析,82 例肥胖的急性淋巴细胞白血病/淋巴瘤(ALL/LL)患儿在诱导化疗期随机接受阿哌沙班预防剂量或标准治疗(不抗凝)。阿哌沙班组主要疗效终点事件 1/42(2.4%)显著低于标准治疗组 10/40(25%),RR 0.09(95%CI 0.01-0.97,P=.007),大出血或临床相关非大出血无统计学显著差异。
要点
- 肥胖 ALL/LL 患儿诱导期阿哌沙班预防使 VTE 事件 1/42(2.4%)vs 标准治疗 10/40(25%)。
- RR 0.09(95%CI 0.01-0.97,P=.007),治疗与肥胖交互作用 P=.03。
- 非肥胖组主要疗效终点无统计学显著差异(RR 0.85,95%CI 0.53-1.37,P=.50)。
核心结论
- 肥胖 ALL/LL 患儿阿哌沙班预防显著降低 VTE 风险且未增加出血。
- 非肥胖组主要疗效终点无统计学显著差异。
研究设计与样本
- PREVAPIX-ALL 为开放标签随机对照试验的事前肥胖亚组分析。
- 82 例肥胖患儿,年龄≥2 至<18 岁,有中心静脉导管,化疗含门冬酰胺酶,随机接受阿哌沙班预防剂量(42 例)或标准治疗(不抗凝,40 例)。
- 主要疗效终点为非致死性症状性和无症状性 VTE 及 VTE 相关死亡的复合终点。
- 主要和次要安全终点分别为大出血和主要及临床相关非大出血(CRNM)的复合终点。
- 试验注册号 NCT02369653。
主要发现
- 主要疗效终点:阿哌沙班组 1/42(2.4%)vs 标准治疗组 10/40(25%),RR 0.09(95%CI 0.01-0.97,P=.007)。
- 治疗与肥胖交互作用有统计学意义,P=.03。
- 非肥胖组主要疗效终点无统计学显著差异(RR 0.85,95%CI 0.53-1.37,P=.50)。
- 大出血或 CRNM 出血无统计学显著差异。
关键数值与推荐
- 肥胖组主要疗效终点:阿哌沙班 1/42(2.4%)vs 标准治疗 10/40(25%),RR 0.09(95%CI 0.01-0.97,P=.007)。
- 非肥胖组主要疗效终点:RR 0.85(95%CI 0.53-1.37,P=.50)。
- 治疗与肥胖交互作用 P=.03。
- 大出血或 CRNM 出血无统计学显著差异。
临床怎么用
- 原文结论为肥胖 ALL/LL 患儿阿哌沙班预防显著降低 VTE 风险且未增加出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric patients with acute lymphoblastic leukemia and lymphoma (ALL/LL) and obesity are at increased risk for venous thromboembolism (VTE). The PREVAPIX-ALL trial was an open-label, randomized, controlled trial assessing the safety and efficacy of apixaban for VTE prevention in pediatric patients with ALL/LL. An a priori subgroup analysis of patients with obesity in the PREVAPIX-ALL trial was planned because of increased VTE risk in this group. Patients with obesity, aged ≥2 to <18 years, central venous catheter, and chemotherapy containing asparaginase were randomized to apixaban (prophylactic dose) vs standard of care (SOC; no anticoagulation) during induction chemotherapy. The primary efficacy end point was a composite of nonfatal symptomatic and asymptomatic VTE and VTE-related death. The primary and secondary safety outcomes were major bleeding and a composite of major and clinically relevant nonmajor (CRNM) bleeding, respectively. A total of 82 PREVAPIX-ALL participants presented with obesity, of whom 42 were randomized to apixaban. For the primary efficacy end point, a significant decrease in VTE events was present in the apixaban arm (1/42 [2.4%]) as compared with the SOC arm (10/40 [25%]; relative risk [RR], 0.09; 95% confidence interval [CI], 0.01-0.97; P = .007). There was a statistically significant treatment obesity interaction, P = .03. No statistically significant difference was observed for the primary efficacy end point among the nonobese group (RR, 0.85; 95% CI, 0.53-1.37; P = .50). No statistically significant difference in major or CRNM bleeding was observed. Apixaban prophylaxis in patients with obesity and ALL/LL resulted in a statistically significant VTE risk reduction with no increase bleeding. This trial was registered at www.clinicaltrials.gov as #NCT02369653.
引用
- Rodriguez V, O'Brien SH, Orgel E, et al. Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia. Blood Adv. 2025. PMID: 40505060. doi:10.1182/bloodadvances.2025016160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。